COPD pipeline expansion, 2026 mid-year reference

Reference layout of the COPD therapeutic pipeline as of mid-2026. Includes established inhaled bronchodilator and inhaled corticosteroid combinations, the emerging biologic class (anti-IL-5 mepolizumab now COPD-approved, anti-IL-33 itepekimab in development, anti-TSLP and adjacent mechanisms), novel small-molecule programs, and the live commercial questions. Useful as a quick orientation for cross-functional teams entering the COPD conversation as the therapeutic frame expands beyond the established inhaler-based class.